Compare Enveric Biosciences Inc (ENVB) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares Core MSCI EAFE ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares Core MSCI EAFE ETF trades at $95.89 (market cap $191.47B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 28620.3× Enveric Biosciences Inc's market cap, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares Core MSCI EAFE ETF for 41 Days on average.
| ENVB | IEFA | |
|---|---|---|
Market Cap | $6.69M | $191.47B |
Volume | 41,141 | 11,673,895 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $101.41 |
52-Week Low | $1.27 | $85.06 |
Typical Hold Time | 14 Days | 41 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
IEFA (iShares Core MSCI EAFE ETF) trades at $96.20, down 1.08% with bearish technical signals from moving averages but neutral oscillators. The ETF provides exposure to developed markets outside North America with $196 billion in assets under management. Recent comparisons highlight its competitive expense ratio of 0.07% and higher dividend yield versus peers like Schwab's SCHF and State Street's SPDW.
The fund faces headwinds from international market volatility and currency risks, though its size and diversification offer stability. Near-term performance may be influenced by global economic conditions and investor rotation away from concentrated U.S. tech exposure. Key support sits at $95 with resistance at $97.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
